-Reuters
Related Posts
FDA Grants Full Approval For Blincyto To Treat Minimal Residual Disease-Positive B-Cell Precursor Acute Lymphoblastic Leukemia
Conversion From Accelerated to Full Approval
Reinforces BLINCYTO as Standard of Care for Patients With Minimal Residual Disease at Baseline After Remission
THOUSAND OAKS, Calif., June 21, 2023 /PRNewswire/ --
Recap: Codexis Q1 Earnings
Codexis (NASDAQ:CDXS) reported its Q1 earnings results on Thursday, May 4, 2023 at 04:05 PM. Here’s what investors…
Curaleaf’s Strategic Move To Attract Deeper-Pocketed Investors, Internal Reorganization Sets Stage For TSX Listing
Curaleaf Holdings, Inc. announced an internal reorganization of its U.S. operations, related to receiving a conditional approval of the Toronto Stock Exchange to list the company's subordinate voting shares on the TSX. The company's wholly-owned subsidiary entered into a subscription agreement with a third-party investor that is not affiliated with the company, Curaleaf USA, or the control person of the company, under which Curaleaf USA issued to the investor one share of Class A voting and non-participating common stock, for an aggregate subscription amount of $1 million. Curaleaf's uplisting to TSX means gaining access to deeper-pocketed investors, a possibility previously hindered due to U.S. federal illegality, which makes the Nasdaq and NYSE nonviable options. Moreover, Curaleaf will join multi-state operator TerrAscend Corp., which is doing business in Canada and the US - and has already secured a listing on TSX this summer.